Overview of Indigo Carmine

Property	Description
Active ingredient	Indigotindisulfonate Sodium
Form	Solution for Injection
Pharmacological class	Diagnostic Agent (Miscellaneous Diagnostic Dye)
Common use	Visualization of the urinary tract during surgery
Origin	Synthetic dye (Organic salt)

Indigo Carmine: A Diagnostic Agent and Urological Aid

Indigo Carmine is a specialized injectable diagnostic agent, chemically known by its active ingredient, Indigotindisulfonate Sodium. It is formally classified as a Miscellaneous Diagnostic Dye. This designation confirms its primary function as a visualization tool used exclusively during professional medical procedures, rather than as a therapeutic drug intended to treat a disease. The product is supplied as a sterile, aqueous solution for injection, intended for parenteral administration.

Indigotindisulfonate Sodium is a synthetic blue dye and an organic salt derived from indigo through sulfonation, a process that ensures its high water-solubility and suitability for clinical use. Its function is clinically recognized for providing high-contrast staining in a surgical field, a property supported by pharmacological studies. While the compound itself is also known as FD&C Blue No. 2 in non-medical contexts, its pharmaceutical preparation adheres to rigorous purity and sterility standards unique to clinical use.

Composition and General Purpose in Medical Procedures

The general purpose of Indigo Carmine is to enhance visual contrast during various surgical procedures, particularly those involving the pelvic and abdominal cavities. Its effect is based on its physiological action of undergoing rapid renal excretion, meaning the kidneys quickly filter the compound from the bloodstream and pass it into the urinary tract.

This process results in the urine being intensely stained a deep blue, which acts as a clear visual marker. This simple yet critical visualization aid allows surgeons to accurately localize the ureteral orifices and confirm the structural integrity of the urinary tract. Indigotindisulfonate Sodium is used for aiding in the cystoscopic assessment of the ureters in adults.

Regulatory References

NCI Drug Dictionary

What side effects are possible with Indigo Carmine?

Possible Side Effects and Safety Information

The safety characteristics of Indigo Carmine (Indigotindisulfonate Sodium) are formally defined by the adverse reactions and constraints documented in official regulatory prescribing information. The adverse event profile focuses significantly on the cardiovascular system and the potential for hypersensitivity.

Officially Documented Adverse Reactions

Adverse reactions are classified by the system-organ class affected, with reactions such as hypertension (transient high blood pressure) and bradycardia (low heart rate) being commonly reported (ge 1%) in official labeling. Gastrointestinal effects, including nausea, vomiting, and constipation, are also listed among common events. The dye is expected to cause a temporary, intense blue discoloration of urine due to its physiological excretion.

Serious adverse events explicitly documented in regulatory sources include cardiac arrest, asystole, arrhythmia, and severe systemic anaphylaxis (a type of serious allergic reaction). These serious cardiovascular events are noted to generally occur within 60 minutes of the diagnostic agent's administration.

Safety Considerations and Limitations

The agent is contraindicated in individuals with a known hypersensitivity to Indigotindisulfonate sodium. A significant safety constraint noted in the labeling is the dye’s ability to interfere with pulse oximetry measurements, which may lead to artifactually low oxygen saturation readings during the procedure. Furthermore, the use of Indigo Carmine is not recommended in patients presenting with severely reduced estimated Glomerular Filtration Rate (eGFR < 30 mL/min), reflecting its dependence on renal excretion. Caution is also advised for patients with pre-existing heart rate or conduction disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Indigotindisulfonate Sodium (Indigo Carmine) is defined by the mandated emergency response to documented severe risks, rather than by specific overdose symptoms.

Documented Overdose Presentation

Regulatory labeling explicitly states that no data are available describing the specific signs, symptoms, or laboratory findings that accompany overdosage. Consequently, no classical presentation of overdosage is formally documented in the official regulatory texts.

When Immediate Medical Help Is Required

Urgent medical attention is required immediately if any signs of the documented severe, acute reactions are observed. The official labeling warns of the potential for severe or life-threatening cardiovascular reactions, including cardiac arrest, arrhythmia, asystole, hypotension, hypertension, bradycardia, and tachycardia. Serious anaphylactic reactions (such as dyspnea, bronchospasm, or urticaria) are also a documented risk that necessitates the immediate availability of emergency medical equipment and trained personnel.

Management and Specific Considerations

The prescribed management for overdose is symptomatic and supportive treatment. Administration of the product must be interrupted immediately if severe reactions are observed. No specific antidote is known. Close monitoring of blood pressure and cardiac rhythm is mandatory during and following injection. Clearance of the dye is primarily renal, meaning its excretion time is prolonged in patients with impaired renal function. Furthermore, the dye may cause a transient, artifactual reduction in SpO2 readings due to interference with pulse oximetry.

Therapeutic Uses of Indigo Carmine

What Indigo Carmine Treats: Main Uses and Benefits

The core use of the diagnostic agent Indigo Carmine (Indigotindisulfonate Sodium) is primarily in the acute setting of surgery, focusing its therapeutic benefit on procedural safety and diagnostic support. The primary application plays a role in managing visualization and assisting in the assessment of urinary tract integrity during complex surgical procedures.

The dye is commonly used to address diagnostic ambiguity when there is a risk of potential injury to the ureters or bladder, which may assist with reducing the potential for complication resulting from an undetected leak or injury. The agent is applied to support anatomical localization of the ureters and their orifices. This supportive function is generally relevant in clinical settings that involve acute or disruptive episodes where additional symptomatic support for diagnostic certainty is needed, such as during urological procedures, gynecological surgery, and extensive abdominal operations in adult patients.

“The primary goal is commonly used to help with the visual management of diagnostic uncertainty regarding urinary tract structures.”

The primary therapeutic benefit helps maintain functional stability during the procedure.

Quick Fact: Support for Surgical Integrity
Symptom/Condition Domain: Conditions presenting with systemic or localized discomfort, specifically those involving procedural risk to the urinary tract.
Common Clinical Scenario: Applied in scenarios where additional management of discomfort or diagnostic ambiguity is required during complex pelvic or abdominal procedures.
Patient Benefit: Supports patients during difficult episodes by assisting with maintaining functional stability and addressing the risk of unrecognized procedural events.

Regulatory References

Official NIH DailyMed Information

Eligibility and Restrictions for Use

Who can and cannot use Indigo Carmine?

Eligibility for Indigo Carmine (Indigotindisulfonate Sodium) is defined by strict criteria in official regulatory labeling, focusing on patient status and specific medical conditions.

Absolute Non-Eligibility (Contraindication)

Indigo Carmine is contraindicated for use in patients with a documented history of hypersensitivity to indigotindisulfonate or any other ingredient in the formulation.

Age and Organ Function Restrictions

The dye is approved for use in adult patients. Safety and effectiveness have not been established in pediatric patients (children and adolescents), meaning its use in these age groups is not recommended under standard labeled conditions.

Use is not recommended for individuals with severe renal impairment (significant kidney function limitations), as the medicine's effectiveness and safety have not been studied in this population.

Conditional and Restricted Use

Patients with certain pre-existing conditions, particularly cardiovascular disorders such as hypertension, low heart rate, or heart conduction disorders, require caution and close monitoring during and following administration.

Regarding reproductive status, the dye is generally not recommended during pregnancy by European authorities, and US labeling advises use only if clearly needed. Caution is also advised for nursing women, as it is unknown if the compound passes into human milk.

What should I know about interactions with other medicines?

The regulatory interaction profile for Indigo Carmine (Indigotindisulfonate Sodium) is defined primarily by specific physical administration restrictions and pharmacodynamic cautions, rather than systemic drug-drug interactions.

Pharmacodynamic and Metabolic Interactions

Official regulatory documents indicate that formal interaction studies have not been performed to characterize metabolic or pharmacokinetic pathways, such as those involving CYP enzymes. Therefore, no formal exposure-modifying interactions are documented in regulatory labeling.

In terms of Pharmacodynamic Interaction Risk, caution is advised regarding the concomitant use of medicines that affect blood pressure, or those that induce bradycardia or affect nitric oxide production. This is noted because the diagnostic agent has the potential to exert a transient pressor effect.

Administration and Clearance Restrictions

A key restriction relates to Physical Incompatibility: to prevent the active substance from precipitating, the solution must not be diluted prior to injection, nor must it be injected using infusion assemblies that have contained other solutions. This is a mandatory constraint for administration.

Furthermore, a Population-Specific Consideration is noted regarding elimination kinetics. Use is not recommended for patients with severe renal impairment (creatinine clearance less than 10 mL/min). This restriction is tied to the diagnostic dye's clearance capacity, which may lead to delayed onset or elimination.

Mechanism of Action

How Indigo Carmine Works

Primary Action: Inhibition of the NO-cGMP Pathway

Indigo Carmine exerts its effect primarily as an inhibitor within the Nitric Oxide ( NO)-cGMP signaling cascade, the system responsible for mediating blood vessel relaxation. The drug interferes with the generation and/or release of NO from the endothelial cells lining the blood vessels. Furthermore, it directly inhibits soluble Guanylyl Cyclase (sGC) in the adjacent vascular smooth muscle. The action on sGC reduces the conversion of GTP to cyclic Guanosine Monophosphate ( cGMP).

Impact on Vascular Tone and Resistance

The suppression of the NO-cGMP vasodilatory system constitutes the core of the mechanistic cascade. This molecular interference prevents the normal signal for vasodilation (vessel widening), shifting the balance toward a constricted state. This physiological modulation leads to an immediate increase in systemic vascular resistance and results in a subsequent increase in arterial blood pressure.

Dosage and Administration Information

Indigo Carmine is administered as a specialized diagnostic aid in a controlled clinical setting, strictly following established guidelines. The primary and preferred route of administration is via intravenous (IV) injection. The drug is supplied as a sterile solution for injection in single-dose ampules, typically dosed at 5 mL (equivalent to 40 mg of Indigotindisulfonate Sodium) for adult patients.

The medicine is intended for acute, procedural use and is administered as a slow injection, typically over one minute. The diagnostic effect—the appearance of blue coloration—is usually observed at the ureteral orifices within a rapid interval of 4 to 9 minutes following the IV administration. If initial visualization is deemed inadequate, the protocol permits the administration of a second 5 mL dose approximately 20 to 30 minutes after the first injection.

Specific preparation and handling steps are mandated to ensure proper administration. The solution must be filtered using a 5 micron or smaller filter straw/needle immediately prior to use and must not be diluted. Any unused portion from the single-dose ampule must be discarded. Regarding specific populations, the medicine is not recommended for use in patients with severe kidney impairment (eGFR <30 mL/min), as its function relies on rapid renal excretion, and its safety has not been established for pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indigo Carmine

Evidence for Use in Urinary Tract Visualization During Surgery

The core research has examined its use as a visualization aid to explore the integrity of the ureters, which are the tubes connecting the kidneys to the bladder. This evidence involves various study designs, including short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that examined data from numerous clinical settings. The research was applied in studies involving adult patients undergoing complex surgical procedures—including urological and gynecological operations—where there is a need to confirm the flow of urine.

Studies monitored outcomes such as the Time to Visualization of the blue dye efflux from the ureteral opening and a measured Visualization Conspicuity Score. Findings from these controlled trials and meta-analyses describe patterns where the use of the dye was associated with Time to Visualization findings that were shorter compared to saline-based methods. Studies report that Visualization Conspicuity Scores measured by reviewers were observed to be higher with the dye. The research explores the dye's role as a distinct visual marker in the surgical field.

The Study Landscape: Short-Term Assessments and Diagnostic Accuracy

This part of the research overview details the specific ways in which the dye's performance was evaluated. The primary outcomes used were acute visualization metrics, meaning they focused on the immediate effect observed by the surgeon during the procedure. The research highlights changes measured during the study period, with a specific focus on short-term changes in visualization. The evidence was evaluated for its role as a visual marker in the setting of the clinical trials, but the study design itself limits insight into patient-reported outcomes describing perceived discomfort.

Evidence in Specific Patient Populations

The primary clinical research on Indigo Carmine was evaluated in a population of adult patients. Studies have explored dose adjustment in patients with mild to moderate renal impairment (a specific level of reduced kidney function). However, the dye has not been studied in patients with severe renal impairment (eGFR below 30 mL/min), meaning data for this group remain insufficient. Research has not yet explored the use of the dye in pediatric patients.

What Remains Uncertain About the Research Evidence

The research highlights key limitations that are typical for diagnostic agents. The current follow-up durations were limited to short-term post-injection periods, meaning there is limited information for long-term outcomes or how the dye’s use affects long-term clinical management. Comparative evidence is lacking for many alternative diagnostic methods that are currently in use, and there remains uncertainty regarding its performance in specific subgroups due to a lack of dedicated research.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Indigo Carmine (FAQ)

Q: Can Indigo Carmine be used to check for leaks or damage?

According to official regulatory documents, Indigo Carmine is indicated for use as a visualization aid. Its primary purpose is the cystoscopic assessment of the integrity of the ureters in adult patients, meaning it helps doctors confirm those structures are intact during surgery.

Q: How is Indigo Carmine stored before use?

Indigo Carmine injection must be stored in its original container at a controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The solution must be protected from light and should not be refrigerated or frozen to maintain its integrity, as noted in the storage requirements.

Q: Does Indigo Carmine contain any common allergens like gluten or latex?

The official product formulation lists the active ingredient, Indigotindisulfonate Sodium, along with Water for Injection and pH adjusters like Citric Acid and Sodium Citrate. Common allergens such as gluten or latex are not listed in the active or inactive ingredients section of the official drug product label.

Q: Is Indigo Carmine often used in obstetric procedures?

Official labeling states the drug is indicated for use in surgical procedures, including urological and gynecological operations. While it is used in surgical settings involving the pelvic area, the specific mention of general obstetric procedures is not in the primary indication for the drug.

Q: What does the FDA say about the safety of Indigo Carmine?

The official FDA labeling includes specific warnings and precautions regarding the drug’s use. These focus on the potential for severe, life-threatening cardiovascular reactions, serious hypersensitivity (allergic) reactions, and the risk of interfering with pulse oximetry readings during the procedure.

Q: Do healthcare providers need special training to administer Indigo Carmine?

Regulatory documents advise that, due to the potential for serious adverse reactions, emergency equipment and trained personnel should be readily available. This is to ensure proper monitoring and management of any potential serious or systemic reactions that may occur after administration.

Q: Does the dose of Indigo Carmine depend on a person's weight?

The standard dose for Indigo Carmine in adults is a fixed volume. However, some regulatory documents note that a reduced dosage may be considered by the prescribing physician in underweight patients to potentially reduce the risk of skin coloration.

Q: Why might a surgeon choose not to use Indigo Carmine?

A surgeon would avoid using Indigo Carmine if a patient has a known allergy or hypersensitivity to the drug. Additionally, the drug is typically avoided in patients with severe kidney impairment or those with pre-existing, high-risk cardiovascular conditions listed in the warnings.

Q: Can Indigo Carmine affect a breastfeeding mother?

It is not currently known whether the drug is excreted into human milk. As a result, the official label advises that caution should be exercised by the healthcare provider when the drug is administered to a woman who is nursing.

Q: What level of evidence exists for using Indigo Carmine in non-urological settings?

The drug is officially indicated for use as a visualization aid specifically in the cystoscopic assessment of the ureters in adults. Its primary clinical research and indication focus heavily on urological and gynecological procedures that require checking the integrity of the urinary tract.

Q: Is the color change from Indigo Carmine always obvious?

Clinical studies have measured visualization conspicuity scores to confirm visibility. However, official regulatory information does not contain a guarantee that the color change will be clearly obvious in every single case.

Q: How can I know if my side effect is related to Indigo Carmine?

Any adverse reactions experienced following administration are important to report to the prescribing healthcare provider. Official labeling lists the reported common and serious adverse reactions that are documented in clinical use.

Q: Is Indigo Carmine available over the counter anywhere in the world?

No, Indigo Carmine is designated as 'Rx Only' (prescription only) by regulatory bodies like the FDA. It is a specialized diagnostic agent intended for use only by or under the direction of a qualified physician in a clinical setting.

Q: What is the chemical composition of Indigo Carmine?

The active substance in the injection is Indigotindisulfonate Sodium, a synthetic blue dye. The solution also contains Water for Injection and pH-adjusting agents, such as Citric Acid or Sodium Citrate.

Q: Why is it administered intravenously rather than orally?

Indigo Carmine is administered intravenously because its diagnostic function relies on rapid, complete excretion by the kidneys. Injecting it directly into the bloodstream allows it to quickly reach the kidneys, appear in the urine, and provide the visualization required for the surgical procedure.

Q: Can Indigo Carmine be used during laparoscopic surgery?

Official indications confirm the drug is used as a visualization aid in a variety of surgical procedures, including open, robotic, or endoscopic surgical procedures. This aligns with its use in modern surgical techniques like laparoscopy, where visual contrast is critical.

Q: Are there any known interactions between Indigo Carmine and common pain relievers?

Formal drug interaction studies that evaluate the effects of Indigo Carmine on other medications, including common pain relievers, have not been performed. Therefore, specific interactions with these drugs are not documented in the official regulatory labeling.

Q: Does Indigo Carmine interact with any vitamins or herbal supplements?

Official regulatory sources state that formal drug interaction studies have not been conducted. As a result, specific interactions between Indigo Carmine and any vitamins or herbal supplements are not documented in the official labeling.

Q: What should I tell my doctor about before receiving Indigo Carmine?

Before administration, it is important to disclose any known drug allergies, especially to Indigotindisulfonate. You should also discuss any history of heart conditions, blood pressure issues, or any known kidney function problems, as these are listed in the warnings.

Q: Is there any research on long-term effects or safety of Indigo Carmine?

Studies on the long-term effects of Indigo Carmine, such as carcinogenicity (cancer-causing potential), have not been conducted using the intravenous administration route. Non-clinical studies by other routes have not shown carcinogenic effects.

Q: What is the maximum time Indigo Carmine can be detected in the body?

Official clinical pharmacology data indicates the drug has a short biological half-life of approximately 4 to 5 minutes following an intravenous injection. This suggests very rapid elimination from the body, though the specific time for complete clearance is not provided.

Q: Does Indigo Carmine interact with diabetes medications?

Since formal drug interaction studies have not been performed for Indigo Carmine, specific interactions with medication classes like diabetes medications are not documented in the official regulatory labeling.

How should Indigo Carmine be stored and disposed of?

How to Store and Dispose of Indigo Carmine

Indigo Carmine Injection must be stored in accordance with specific regulatory requirements to maintain its integrity.

Official Storage Conditions

Requirement	Description
Temperature	Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).
Environmental	The product must be protected from light and not refrigerated or frozen.
Container	Keep the injection in its original container until use.
Stability	The solution must be used immediately after opening the ampule, and any unused portion must be discarded.
Child Safety	The medicine must be stored out of the reach of children.

Disposal Instructions

Any unused Indigo Carmine Injection or waste materials must be disposed of in accordance with local requirements for medicinal waste.

Indigo Carmine